Cucarull, B., Tutusaus, A., Subías, M., Stefanovic, M., Hernáez-Alsina, T., Boix, L., . . . Morales, A. (2020). Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers (Basel).
Styl cytowania ChicagoCucarull, Blanca, et al. "Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models." Cancers (Basel) 2020.
Styl cytowania MLACucarull, Blanca, et al. "Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models." Cancers (Basel) 2020.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..